膀胱癌：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計義大利膀胱癌市場將從 2025 年的 4.2 億美元成長到 2035 年的 9.9 億美元。
• 市場成長的驅動力是免疫腫瘤療法的普及和診斷率的提高。
• 未來的發展取決於標靶治療和聯合治療策略的進步。

膀胱癌概述

膀胱癌是泌尿系統最常見的惡性腫瘤，其主要組織學亞型為尿路上皮癌，起源於膀胱黏膜的移行上皮。吸菸、職業性接觸芳香胺、慢性膀胱炎、接觸環Cyclophosphamide是已知的危險因子。 FGFR3、TP53、RB1 和 PIK3CA 的體細胞突變可促進整個頻譜（包括非肌肉層浸潤性和肌層浸潤性）的致癌性轉化。患者會出現無痛性肉眼血尿（主要症狀），以及頻尿、尿急和排尿困難。膀胱鏡檢查和切片檢查仍然是診斷的黃金標準，上泌尿道影像檢查和 CT造影可作為輔助手段。非肌肉層浸潤性膀胱癌採用經尿道切除術進行內視鏡治療，對於高風險病例，膀胱內灌注卡介苗（BCG）免疫療法可降低復發和進展的風險。此外，Pembrolizumab已核准用於治療對BCG無反應的原位癌。對於肌肉層浸潤性膀胱癌，通常先進行以Cisplatin為基礎的新輔助化療，隨後行根治根治性膀胱切除術或以保留膀胱為目標的三聯聯合治療。對於轉移性疾病，以含鉑類藥物為基礎的化療，在含鉑類藥物化療有效後，使用Avelumab進行維持免疫治療已被證實可顯著延長存活期。厄達替尼針對FGFR3突變的轉移性疾病，而恩福坦布-維多汀（抗體藥物複合體偶聯物）與Pembrolizumab的聯合治療已成為轉移性疾病的一線治療方案，具有突破性意義。預後因疾病階段而異，但多學科管理、膀胱鏡後續觀察以及以患者為中心的生活品質最佳化對於長期照護至關重要。

主要亮點

• 在德國，根據存活率調整後，膀胱癌患者人數預計將從 2025 年的 727,014 人增加到 2035 年的 777,528 人。
• 人口老化和吸菸相關危險因子的不斷增加，持續推高了該疾病的盛行率。
• 免疫療法和標靶治療的日益普及正在改變治療疾病的方式。
• 進行性和復發性膀胱癌的治療仍有未滿足的需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准和順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Merck Sharp &Dohme LLC
• Ferring Pharmaceuticals
• ImmunityBio, Inc.
• Lipac Oncology LLC
• Daiichi Sankyo
• UroGen Pharma Ltd.
• CG Oncology, Inc.
• Astellas Pharma Global Development, Inc.
• Zhuhai Beihai Biotech Co., Ltd.
• ALX Oncology Inc.
• Hoffmann-La Roche
• Protara Therapeutics
• Monopar Therapeutics
• Eli Lilly and Company
• Incyte Corporation
• ViroMissile, Inc.
• Genentech, Inc.
• Palleon Pharmaceuticals, Inc.
• NGM Biopharmaceuticals, Inc.
• Toray Industries, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• AstraZeneca
• Sensei Biotherapeutics, Inc.
• Beijing Biotech
• OncoC4, Inc.
• MacroGenics
• Pfizer
• OncoNano Medicine, Inc.
• Medicenna Therapeutics, Inc.
• EvolveImmune United, Inc.

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Bladder Cancer Market Outlook

Thelansis's "Bladder Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bladder Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bladder Cancer Overview

Bladder cancer is the most common malignancy of the urinary tract, with urothelial carcinoma representing the predominant histological subtype, arising from the transitional epithelium lining the bladder mucosa. Tobacco smoking, occupational aromatic amine exposure, chronic bladder inflammation, and cyclophosphamide exposure are established risk factors, with somatic mutations in FGFR3, TP53, RB1, and PIK3CA driving oncogenic transformation across non-muscle-invasive and muscle-invasive disease spectrums. Patients present with painless macroscopic haematuria - the cardinal symptom - alongside urinary frequency, urgency, and dysuria; cystoscopy with biopsy remains the diagnostic gold standard, supplemented by upper tract imaging and CT urography. Non-muscle-invasive bladder cancer is managed endoscopically via transurethral resection, with intravesical BCG immunotherapy reducing recurrence and progression risk in high-risk disease; pembrolizumab is approved for BCG-unresponsive carcinoma in situ. Muscle-invasive disease warrants neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or bladder-preserving trimodality therapy. Metastatic disease is addressed with platinum-based chemotherapy, while maintenance avelumab immunotherapy following platinum response has demonstrated meaningful survival benefit. Erdafitinib targets FGFR3-altered metastatic disease, and enfortumab vedotin - a Nectin-4 directed antibody-drug conjugate - alongside pembrolizumab represents a transformative first-line metastatic standard. Prognosis varies with stage; multidisciplinary management, surveillance cystoscopy, and patient-centred quality-of-life optimisation are integral to long-term care.

Key Highlights

• In Germany, survival-adjusted prevalent Bladder Cancer cases are projected to increase from 727,014 in 2025 to 777,528 by 2035.
• Rising aging population and smoking-related risk burden continue to drive disease prevalence.
• Increasing adoption of immunotherapies and targeted agents is reshaping the treatment landscape.
• Persistent unmet need exists in advanced and recurrent bladder cancer management.

Market Overview

• The Italy Bladder Cancer market is projected to grow from USD 420 million in 2025 to USD 990 million by 2035.
• Market growth is driven by increasing uptake of immuno-oncology therapies and improved diagnosis rates.
• Future expansion will depend on advances in targeted therapies and combination treatment strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Ferring Pharmaceuticals
• ImmunityBio, Inc.
• Lipac Oncology LLC
• Daiichi Sankyo
• UroGen Pharma Ltd.
• CG Oncology, Inc.
• Astellas Pharma Global Development, Inc.
• Zhuhai Beihai Biotech Co., Ltd.
• ALX Oncology Inc.
• Hoffmann-La Roche
• Protara Therapeutics
• Monopar Therapeutics
• Eli Lilly and Company
• Incyte Corporation
• ViroMissile, Inc.
• Genentech, Inc.
• Palleon Pharmaceuticals, Inc.
• NGM Biopharmaceuticals, Inc.
• Toray Industries, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• AstraZeneca
• Sensei Biotherapeutics, Inc.
• Beijing Biotech
• OncoC4, Inc.
• MacroGenics
• Pfizer
• OncoNano Medicine, Inc.
• Medicenna Therapeutics, Inc.
• EvolveImmune United, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)